Cellebrite DI Financial Statements
NASDAQ: CLBTTechnologyComputer Software: Prepackaged SoftwareUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cellebrite DI revenue and earnings
In fiscal 2025, Cellebrite DI generated $475.7 million in revenue, up 18.6% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $78.3 million, for a net margin of 16.5% versus a median of 3.0% in the prior 5 years. Gross margin was 84.2% (down from 84.4%) and operating margin 14.0%.
Diluted earnings per share came in at $0.31. Over the last 5 fiscal years, CLBT's revenue has grown at a 19.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Cellebrite DI income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20222023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 475.68M | 401.20M | 325.11M | 270.65M | 246.25M | 194.91M | 171.85M |
| Revenue growth (YoY) | +18.56% | +23.41% | +20.12% | +9.91% | +26.34% | +13.42% | — |
| Cost of Revenue | 75.17M | 62.59M | 53.23M | 50.75M | 42.56M | 37.88M | 35.82M |
| Gross Profit | 400.50M | 338.61M | 271.88M | 219.91M | 203.69M | 157.03M | 136.03M |
| Operating Expenses | 334.02M | 281.70M | 238.64M | 218.86M | 189.87M | 147.82M | 137.55M |
| Research & Development | 113.88M | 98.42M | 84.39M | 80.62M | 65.54M | 54.38M | 46.57M |
| Selling, General & Admin | 220.15M | 183.29M | 154.26M | 138.24M | 124.33M | 93.44M | 90.98M |
| Operating Income | 66.48M | 56.91M | 33.24M | 1.04M | 13.82M | 9.22M | -1.52M |
| Other Income (Expense) | 24.20M | -332.89M | -108.80M | 119.72M | 68.48M | 2.18M | 2.94M |
| Pretax Income | 90.68M | -275.98M | -75.56M | 120.76M | 82.31M | 11.40M | 1.42M |
| Income Tax | 12.35M | 7.02M | 5.54M | -45.00K | 10.91M | 5.62M | 3.29M |
| Net Income | 78.33M | -283.01M | -81.10M | 120.81M | 71.40M | 5.78M | -1.88M |
| Net Income growth (YoY) | — | — | -167.13% | +69.20% | +1135.01% | — | — |
| EPS (Basic) | 0.32 | -1.35 | -0.43 | 0.64 | 0.49 | -0.08 | -0.08 |
| EPS (Diluted) | 0.31 | -1.35 | -0.43 | 0.59 | 0.44 | -0.08 | -0.08 |
| Shares Outstanding (Basic) | 241.63M | 209.47M | 190.15M | 182.69M | 144.00M | 123.70M | 121.56M |
| Shares Outstanding (Diluted) | 249.90M | 209.47M | 190.15M | 195.39M | 161.54M | 123.70M | 121.56M |
| EBITDA | 78.35M | 67.51M | 43.25M | 10.24M | 20.83M | 15.10M | 2.56M |
| Gross Margin | 84.20% | 84.40% | 83.63% | 81.25% | 82.72% | 80.57% | 79.15% |
| Operating Margin | 13.98% | 14.18% | 10.22% | 39.00% | 5.61% | 4.73% | -88.00% |
| Net Margin | 16.47% | -70.54% | -24.95% | 44.63% | 28.99% | 2.97% | -109.00% |
This table shows 7 annual periods of Cellebrite DI's income statement, from FY 2025 back to FY 2019, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CLBT's reporting calendar. What is a income statement?